164 related articles for article (PubMed ID: 9093724)
21. Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.
Focan C; Graas MP; Beauduin M; Canon JL; Salmon JP; Jerusalem G; Focan-Henrard D; Lobelle JP; Schallier D
Anticancer Res; 2005; 25(2B):1211-7. PubMed ID: 15865068
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
[TBL] [Abstract][Full Text] [Related]
23. Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer.
Bonneterre J; Dieras V; Tubiana-Hulin M; Bougnoux P; Bonneterre ME; Delozier T; Mayer F; Culine S; Dohoulou N; Bendahmane B
Br J Cancer; 2004 Oct; 91(8):1466-71. PubMed ID: 15381937
[TBL] [Abstract][Full Text] [Related]
24. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
[TBL] [Abstract][Full Text] [Related]
25. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
[TBL] [Abstract][Full Text] [Related]
26. Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial.
Tan QW; Luo T; Zheng H; Tian TL; He P; Chen J; Zeng HL; Lv Q
Chin J Cancer; 2017 Mar; 36(1):27. PubMed ID: 28270181
[TBL] [Abstract][Full Text] [Related]
27. Clinical comparison of safety and efficacy of vinorelbine/epirubicin (NE) with fluorouracil/epirubicin/cyclophosphamide (FEC).
Yan PW; Huang XE; Jiang Y; Tang JH; Xu HX; Xu X; Jin X
Asian Pac J Cancer Prev; 2010; 11(4):1115-8. PubMed ID: 21133634
[TBL] [Abstract][Full Text] [Related]
28. Epirubicin versus mitoxantrone in combination chemotherapy for metastatic breast cancer.
Pavesi L; Preti P; Da Prada G; Pedrazzoli P; Poggi G; Robustelli della Cuna G
Anticancer Res; 1995; 15(2):495-501. PubMed ID: 7763029
[TBL] [Abstract][Full Text] [Related]
29. Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer.
Scinto AF; Ferraresi V; Campioni N; Tonachella R; Piarulli L; Sacchi I; Giannarelli D; Cognetti F
Ann Oncol; 1995 Sep; 6(7):665-71. PubMed ID: 8664187
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant FEC 100 for operable breast cancer: eight-year experience at Centre Jean Perrin.
Mouret-Reynier MA; Abrial CJ; Ferrière JP; Amat S; Curé HD; Kwiatkowski FG; Feillel VA; Lebouëdec G; Penault-Llorca FM; Chollet PJ
Clin Breast Cancer; 2004 Oct; 5(4):303-7. PubMed ID: 15507178
[TBL] [Abstract][Full Text] [Related]
31. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
[TBL] [Abstract][Full Text] [Related]
32. Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: a comparative randomized multicenter study in metastatic breast carcinoma.
Periti P; Pannuti F; Della Cuna GR; Mazzei T; Mini E; Martoni A; Preti P; Ercolino L; Pavesi L; Ribecco A
Cancer Invest; 1991; 9(3):249-55. PubMed ID: 1913227
[TBL] [Abstract][Full Text] [Related]
33. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.
Del Mastro L; Venturini M; Lionetto R; Carnino F; Guarneri D; Gallo L; Contu A; Pronzato P; Vesentini L; Bergaglio M; Comis S; Rosso R
J Clin Oncol; 2001 Apr; 19(8):2213-21. PubMed ID: 11304774
[TBL] [Abstract][Full Text] [Related]
34. Randomized trial comparing conventional intravenous bolus FEC and FEC with high-dose infusional 5-fluorouracil as first-line treatment of advanced breast cancer.
Hebbar M; Bonneterre J; Fournier C; Vanlemmens L; Pion JM; Adenis A; Kamus E; Hecquet B; Conroy T; Tubiana-Hulin M
J Infus Chemother; 1995; 5(4):201-5. PubMed ID: 8934728
[TBL] [Abstract][Full Text] [Related]
35. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Roché H; Fumoleau P; Spielmann M; Canon JL; Delozier T; Serin D; Symann M; Kerbrat P; Soulié P; Eichler F; Viens P; Monnier A; Vindevoghel A; Campone M; Goudier MJ; Bonneterre J; Ferrero JM; Martin AL; Genève J; Asselain B
J Clin Oncol; 2006 Dec; 24(36):5664-71. PubMed ID: 17116941
[TBL] [Abstract][Full Text] [Related]
36. The Canadian experience with intensive fluorouracil, epirubicin and cyclophosphamide in patients with early stage breast cancer.
Levine MN; Bramwell V; Pritchard K; Perrault D; Findlay B; Abu-Zahra H; Warr D; Arnold A; Skillings J
Drugs; 1993; 45 Suppl 2():51-9; discussion 58-9. PubMed ID: 7693423
[TBL] [Abstract][Full Text] [Related]
37. Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer. Cooperative Group of Study and Treatment of Breast Cancer.
Riccardi A; Brugnatelli S; Giordano M; Danova M; Pugliese P; Tinelli C; Klersy C; Richetti A; Fava S; Nastasi G; Rinaldi E; Fregoni V; De Monte A; Trotti G; Bovio A; Ascari E
Tumori; 1998; 84(5):540-6. PubMed ID: 9862513
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase II study of FEC day 1 + 8 and FEC day 1 in patients with advanced breast cancer.
van Toorn DW; Nortier JW; Rubach M; de Swart CA; Huldij JC; van Tinteren H; Vermorke JB
Breast Cancer Res Treat; 2000 Mar; 60(1):57-62. PubMed ID: 10845809
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial.
Zielinski C; Beslija S; Mrsic-Krmpotic Z; Welnicka-Jaskiewicz M; Wiltschke C; Kahan Z; Grgic M; Tzekova V; Inbar M; Cervek J; Chernozemsky I; Szanto J; Spanik S; Wagnerova M; Ghilezan N; Pawlega J; Vrbanec D; Khamtsov D; Soldatenkova V; Brodowicz T
J Clin Oncol; 2005 Mar; 23(7):1401-8. PubMed ID: 15735116
[TBL] [Abstract][Full Text] [Related]
40. A phase II study on the safety and efficacy of 5-fluorouracil, epirubicin, cyclophosphamide (FEC) followed by paclitaxel in the adjuvant treatment of breast cancer.
Erman M; Baltali E; Karaoglu A; Abali H; Engin H; Ozisik Y; Guler N; Altundag K; Tekuzman G; Atahan IL; Onat D; Sayek I
Cancer Invest; 2005; 23(3):215-21. PubMed ID: 15945507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
